CoChat

Real-time continuous glucose monitoring in preterm infants (REACT): an international, open-label, randomised controlled trial

Open access
Beardsall, Kathryn, Thomson, Lynn, Guy, Catherine, Iglesias-Platas, Isabel, van Weissenbruch, Mirjam M, Bond, Simon, Allison, Annabel, Kim, Sungwook, Petrou, Stavros, Pantaleo, Beatrice, Hovorka, Roman, Dunger, David, Molnar, Zoltan, Barlow, Sheula, Baugh, Sharon, Johnson, Kathryn, Uryn, Lindsay, Spencer, Collette, Hubbard, Maria, Somisetty, Sateeshkumar, Adesiyan, Olaitan, Kapadia, Jogesh, Millar, Yvonne, Gurusamy, Kalyana, Bibb, Lindsay, Jones, Kathryn, Heaver, Richard, Muthukumar, Priya, Nichols, Amy, Johnson, Mark, Pond, Jenny, Crowley, Philippa, Mellish, Christie, Shah, Divyen D, Abraham, Mercy, Vincent, Presillina, Anil kumar, Suma, Iringan, Angelina, Aninakwa, Barbara, Dalangin-Chalmers, R A, de Lange, Annemieke · 2021 · The Lancet Child & Adolescent Health
Cited by 82

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Hyperglycaemia and hypoglycaemia are common in preterm infants and have been associated with increased risk of mortality and morbidity. Interventions to reduce risk associated with these exposures are particularly challenging due to the infrequent measurement of blood glucose concentrations, with the potential of causing more harm instead of improving outcomes for these infants. Continuous glucose monitoring (CGM) is widely used in adults and children with diabetes to improve glucose control, but has not been approved for use in neonates. The REACT trial aimed to evaluate the efficacy and safety of CGM in preterm infants requiring intensive care. METHODS: This international, open-label, randomised controlled trial was done in 13 neonatal intensive care units in the UK, Spain, and the Netherlands. Infants were included if they were within 24 h of birth, had a birthweight of 1200 g or less, had a gestational age up to 33 weeks plus 6 days, and had parental written informed consent. Infants were randomly assigned (1:1) to real-time CGM or standard care (with masked CGM for comparison) using a central web randomisation system, stratified by recruiting centre and gestational age (<26 or ≥26 weeks). The primary efficacy outcome was the proportion of time sensor glucose concentration was 2·6-10 mmol/L for the first week of life. Safety outcomes related to hypoglycaemia (glucose concentrations <2·6 mmol/L) in the first 7 days of life. All outcomes were assessed on the basis of intention to treat in the full analysis set with available data. The study is registered with the International Standard Randomised Control Trials Registry, ISRCTN12793535. FINDINGS: Between July 4, 2016, and Jan 27, 2019, 182 infants were enrolled, 180 of whom were randomly assigned (85 to real-time CGM, 95 to standard care). 70 infants in the real-time CGM intervention group and 85 in the standard care group had CGM data and were included in the primary analysis. Compared with infants in the standard care group, infants managed using CGM had more time in the 2·6-10 mmol/L glucose concentration target range (mean proportion of time 84% [SD 22] vs 94% [11]; adjusted mean difference 8·9% [95% CI 3·4-14·4]), equivalent to 13 h (95% CI 5-21). More infants in the standard care group were exposed to at least one episode of sensor glucose concentration of less than 2·6 mmol/L for more than 1 h than those in the intervention group (13 [15%] of 85 vs four [6%] of 70). There were no serious adverse events related to the use of the device or episodes of infection. INTERPRETATION: Real-time CGM can reduce exposure to prolonged or severe hyperglycaemia and hypoglycaemia. Further studies using CGM are required to determine optimal glucose targets, strategies to obtain them, and the potential effect on long-term health outcomes. FUNDING: National Institute for Health Research Efficacy and Mechanisms Evaluation Programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-4642(20)30367-9

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 82

Metadata

Authors
Beardsall, K., Thomson, L., Guy, C., Iglesias-Platas, I., van Weissenbruch, M. M., Bond, S., Allison, A., Kim, S., Petrou, S., Pantaleo, B., Hovorka, R., Dunger, D., Molnar, Z., Barlow, S., Baugh, S., Johnson, K., Uryn, L., Spencer, C., Hubbard, M., Somisetty, S., Adesiyan, O., Kapadia, J., Millar, Y., Gurusamy, K., Bibb, L., Jones, K., Heaver, R., Muthukumar, P., Nichols, A., Johnson, M., Pond, J., Crowley, P., Mellish, C., Shah, D. D., Abraham, M., Vincent, P., Anil kumar, S., Iringan, A., Aninakwa, B., Dalangin-Chalmers, R. A., & de Lange, A.
Venue
The Lancet Child & Adolescent Health
Publisher
Elsevier BV
Published
2021-04
Volume
5
Issue
4
Pages
265-273
ISSN
2352-4642 (ISSN-L)
OpenAlex
W3127748499
Cited by
82
References
4
FWCI
8.72
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-time continuous glucose monitoring in preterm infants (REACT): an international, open-label, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2352-4642(20)30367-9
The paper
Beardsall, K., Thomson, L., Guy, C., Iglesias-Platas, I., van Weissenbruch, M. M., Bond, S., Allison, A., Kim, S., Petrou, S., Pantaleo, B., Hovorka, R., Dunger, D., Molnar, Z., Barlow, S., Baugh, S., Johnson, K., Uryn, L., Spencer, C., Hubbard, M., . . . de Lange, A. (2021). Real-time continuous glucose monitoring in preterm infants (REACT): an international, open-label, randomised controlled trial. The Lancet Child & Adolescent Health. https://doi.org/10.1016/s2352-4642(20)30367-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.